real-time news and commentary for investors
Monday, Sep 23
Sarepta soars again, Prosensa slides further
- The divergence of fortunes for Prosensa (RNA -2.9%) and Sarepta Therapeutics (SRPT +11.8%) continues today, as investors and analysts digest Friday's drisapersen data.
- SRPT is up double-digits for a second session, bringing gains since Thursday to ~31%.
- Meanwhile, RNA extends its losses as Wedbush says the company's call "suggests the anticipated causes for concern with [DEMAND-III] did not result in its failure, which ... calls into question drisapersen's therapeutic activity.”
- Previous coverage